Anatara Lifesciences Ltd (AU:ANR) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Anatara Lifesciences has paused recruitment for its GaRP-IBS clinical trial after exceeding participant targets, with results expected in March 2025. The company is also offering a Share Purchase Plan to raise funds for this trial and an anti-obesity project. This strategic move could intrigue investors interested in the biotech sector as it positions the company for upcoming developments.
For further insights into AU:ANR stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Deutsche Bank Pounds the Table on Broadcom Stock
- ‘Get in for 2025 Gains,’ Says Cowen on Amazon Stock
- Top Analyst Sets the Stage for Nike Stock Ahead of Earnings
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
